Skip to main content
. 2020 May 16;10(14):6430–6447. doi: 10.7150/thno.43177

Figure 10.

Figure 10

Application of ZIKV-Nluc for immunological protection evaluation. (A) Schematic representation of bioluminescence imaging of 3-4 weeks old AG6 mice receiving a mixture of ZIKV-Nluc and pooled immune serum, #22-1. (B) The viral spread from the ventral view of ZIKV-Nluc-infected mice was monitored in real time at the indicated times. (C) The average radiance of ZIKV-Nluc-infected mice was determined by ROI analysis of the ventral side. (D) Bioluminescence imaging of 3-4-week-old AG6 mice that received nine doses of #22-1. (E) The viral spread from the ventral view of ZIKV-Nluc-infected mice was monitored in real time at the indicated times. (F) The average radiance of ZIKV-Nluc-infected mice was determined by ROI analysis of the ventral side. Data represent the mean ± SD analysed by Student's t-test (two tailed) (*, P < 0.05; **, P < 0.01; ***, P < 0.001).